# Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults

> **NCT01479296** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 90 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C)
- **BIOLOGICAL:** rAd5 env A
- **BIOLOGICAL:** rAd5 env B
- **BIOLOGICAL:** rAd5 env C
- **BIOLOGICAL:** rAd5 gag-pol
- **BIOLOGICAL:** Placebo Vaccine

## Key facts

- **NCT ID:** NCT01479296
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2013-05
- **Final completion:** 2017-11-27
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2021-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01479296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01479296, "Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01479296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*